Tempest Therapeutics Inc.(TPST),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

TPST Tempest Therapeutics Inc.

Market Closed 09-25 16:00:00 EDT

0.8290

-0.0210

-2.47%

盘后0.8225

-0.0065-0.78%

19:50 EDT

High0.8946	Low0.8150	Vol288.28K
Open0.8677	D1 Closing0.8500	Amplitude9.36%
Mkt Cap13.71M	Tradable Cap9.50M	Total Shares16.54M
T/O241.28K	T/O Rate2.52%	Tradable Shares11.46M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"TPST","market":"US","secType":"STK","nameCN":"Tempest Therapeutics Inc.","latestPrice":0.829,"timestamp":1790366400000,"preClose":0.85,"halted":0,"volume":288282,"hourTrading":{"tag":"盘后","latestPrice":0.8225,"preClose":0.829,"latestTime":"19:50 EDT","volume":5161,"amount":4276.0822,"timestamp":1790380202812,"change":-0.0065,"changeRate":-0.007841,"amplitude":0.057298},"delay":0,"changeRate":-0.0247058823529412,"floatShares":11460700,"shares":16539767,"eps":-4.561698,"marketStatus":"Market Closed","change":-0.021,"latestTime":"09-25 16:00:00 EDT","open":0.8677,"high":0.8946,"low":0.815,"amount":241275.2559876,"amplitude":0.093647,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.561698,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1790582400000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":0.85,"preHourTrading":{"tag":"盘前","latestPrice":0.862,"preClose":0.85,"latestTime":"09:20 EDT","volume":7254,"amount":6321.5352954,"timestamp":1790342427778,"change":0.012,"changeRate":0.014118,"amplitude":0.071647},"postHourTrading":{"tag":"盘后","latestPrice":0.8225,"preClose":0.829,"latestTime":"19:50 EDT","volume":5161,"amount":4276.0822,"timestamp":1790380202812,"change":-0.0065,"changeRate":-0.007841,"amplitude":0.057298},"volumeRatio":0.12482352345789796,"impliedVol":1.4125,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/TPST/tweets","defaultTab":"tweets","newsList":[{"id":"2670424113","title":"Tempest Therapeutics - Prospectus Filed for Offer and Resale of up to 9,534,164 Shares of Common Stock - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2670424113","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670424113?lang=en_us&edition=fundamental","pubTime":"2026-09-26 04:31","pubTimestamp":1790368270,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260925:nFWN45H0LB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TPST","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669914614","title":"Tempest Therapeutics Inc : H.c. Wainwright Cuts Target Price to $7 from $11","url":"https://stock-news.laohu8.com/highlight/detail?id=2669914614","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669914614?lang=en_us&edition=fundamental","pubTime":"2026-09-24 23:18","pubTimestamp":1790263113,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260924:nFWN45G12Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TPST","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669483478","title":"Tempest Therapeutics Appoints Nancy Freda-Smith to Board, Names Her Audit Committee Chair","url":"https://stock-news.laohu8.com/highlight/detail?id=2669483478","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669483478?lang=en_us&edition=fundamental","pubTime":"2026-09-23 20:04","pubTimestamp":1790165045,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics appoints Nancy Freda-Smith to board, names her audit committee chairTempest Therapeutics appointed Nancy Freda-Smith to its board of directors.Freda-Smith will serve as chair of t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nNDL7YSwK8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","IE00BQXX3C00.GBP","SG9999014013.SGD","RL","IE00BQXX3D17.EUR","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","LU2095319765.USD","BK4202","IE00BQXX3F31.USD","BK4585","TPST","STYL","IE00B64PRP62.GBP","SG9999014005.SGD","LU0963586101.USD","LU0006061336.USD","LU2210149790.SGD","NDAQ","BK4112","LU0314104364.USD","LU0054578231.USD","IE00BKPKM429.USD","BK4588","IE00BGHQF748.EUR","SG9999014039.USD","IE00BN0W2V16.EUR","SG9999014021.USD","BCDF","LU2210150020.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669978483","title":"Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2669978483","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669978483?lang=en_us&edition=fundamental","pubTime":"2026-09-23 20:00","pubTimestamp":1790164801,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nTUA9NVFL4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TPST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668299752","title":"Tempest Therapeutics Signs Exclusive Option Deal with Senlang for CD7-Targeted in Vivo CAR-T Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2668299752","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668299752?lang=en_us&edition=fundamental","pubTime":"2026-09-18 05:06","pubTimestamp":1789679175,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics signs exclusive option deal with Senlang for CD7-targeted in vivo CAR-T platformTempest Therapeutics entered an exclusive option agreement with Hebei Senlang Biotechnology to lice","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260917:nNDLmQCqz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TPST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668686935","title":"Tempest Therapeutics Special Meeting Adjourned After Proposal Fell Short of 75% Vote Threshold","url":"https://stock-news.laohu8.com/highlight/detail?id=2668686935","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668686935?lang=en_us&edition=fundamental","pubTime":"2026-09-17 04:38","pubTimestamp":1789591092,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics special meeting adjourned after proposal fell short of 75% vote thresholdTempest Therapeutics held a reconvened special shareholder meeting on Sept. 15, 2026 to vote on a charter ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nNDL8Cnm5F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TPST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667335600","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2667335600","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667335600?lang=en_us&edition=fundamental","pubTime":"2026-09-16 19:12","pubTimestamp":1789557137,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics  stock was 45% higher in Wednesday's premarket activity, a day after the company said it signed an exclusive option agreement with China's Hebei Senlang Biotechnology.ReTo Eco-Solutions  shares were up over 41% following a more than 676% rise in the prior session.YYForce  stock was 23% higher after the company reported its estimated total and net assets.Future FinTech Group  shares were up 12%, swinging from a 29% fall at Tuesday's close.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4120","BK4011","BK4122","BK4164","YFOR","BK4139","RETO","TPST","FTFT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667627808","title":"Tempest Therapeutics Gains Option to License New In-Body CAR-T Technology From Senlang","url":"https://stock-news.laohu8.com/highlight/detail?id=2667627808","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667627808?lang=en_us&edition=fundamental","pubTime":"2026-09-16 05:45","pubTimestamp":1789508730,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics  signed an exclusive option agreement with China's Hebei Senlang Biotechnology to license a clinical-stage technology that delivers CAR-T cancer treatments directly inside the body, along with a portfolio of related drug candidates.The portfolio includes an early-stage treatment that targets two proteins linked to multiple myeloma and is now being tested in a phase 1 study, Tempest said Tuesday in a statement. Other candidates in the group are aimed at blood cancers and autoimmune diseases, the company said.Tempest said it will continue to evaluate phase 1 results with Senlang during the option period.The company also disclosed in a regulatory filing that it raised about $2.5 million last week through a private placement of prefunded and common stock warrants.Tempest shares rose 35% in after-hours trading.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","TPST","BK4007","BK4539","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667862498","title":"Tempest Secures Exclusive Option to License Clinical-Stage Cd7-Targeted Lentiviral in Vivo CAR-T Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2667862498","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667862498?lang=en_us&edition=fundamental","pubTime":"2026-09-16 04:05","pubTimestamp":1789502700,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260915:nTUA1GSKBQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TPST","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667624994","title":"Tempest Therapeutics Inc: Entered into an Exclusive Option Agreement with Hebei Senlang Biotechnology Co., Ltd","url":"https://stock-news.laohu8.com/highlight/detail?id=2667624994","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667624994?lang=en_us&edition=fundamental","pubTime":"2026-09-16 04:05","pubTimestamp":1789502700,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260915:nTUA1GSKBQ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TPST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667462498","title":"Tempest Therapeutics - no Grade 3 or Higher Cytokine Release Syndrome or Neurotoxicity as of Aug 25, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2667462498","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667462498?lang=en_us&edition=fundamental","pubTime":"2026-09-16 04:05","pubTimestamp":1789502700,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260915:nTUA1GSKBQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TPST","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666228095","title":"Tempest Therapeutics announces $7.5M private placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2666228095","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666228095?lang=en_us&edition=fundamental","pubTime":"2026-09-11 20:30","pubTimestamp":1789129829,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics (TPST) announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 3,105,591 shares ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tempest-therapeutics-announces-7-5m-private-placement-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tempest-therapeutics-announces-7-5m-private-placement-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","TPST","BK4539","LENZ","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666737521","title":"Tempest Therapeutics Prices $2.5 Million Private Placement at $0.81 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2666737521","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666737521?lang=en_us&edition=fundamental","pubTime":"2026-09-11 20:01","pubTimestamp":1789128119,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics prices $2.5 million private placement at $0.81 per shareTempest Therapeutics priced a private placement of 3,105,591 common shares or pre-funded warrants at USD 0.81 with Series C","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nNDL69YqFK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","BK4585","SG9999014039.USD","IE00BQXX3D17.EUR","IE00B3QW5Z07.USD","LU2210149790.SGD","BK4139","IE00BQXX3F31.USD","TPST","IE00BN0W2T93.GBP","LU2095319765.USD","NDAQ","IE00BQXX3C00.GBP","BCDF","LU2210150020.SGD","BK4112","SG9999014013.SGD","IE00BKPKM429.USD","IE00BN0W2W23.USD","IE00B64PRP62.GBP","LU0314104364.USD","IE00BGHQF748.EUR","SG9999014021.USD","BK4588","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666521252","title":"Tempest Therapeutics Announces up to $7.5 Million Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2666521252","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666521252?lang=en_us&edition=fundamental","pubTime":"2026-09-11 20:00","pubTimestamp":1789128001,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nTUA3KQ0DY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TPST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665378956","title":"Tempest Therapeutics CEO to Present at H.C. Wainwright Global Investment Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2665378956","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665378956?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:34","pubTimestamp":1788870887,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics CEO to present at H.C. Wainwright Global Investment ConferenceTempest Therapeutics’ CEO Matt Angel will present at the H.C. Wainwright 28th Annual Global Investment Conference on ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDL8gk7Fj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","SG9999014013.SGD","SG9999014039.USD","IE00BQXX3D17.EUR","SG9999014021.USD","IE00BKPKM429.USD","LU2095319765.USD","IE00BQXX3C00.GBP","IE00BGHQF748.EUR","TPST","BK4585","BK4139","LU2210150020.SGD","BK4112","BCDF","IE00B3QW5Z07.USD","IE00BQXX3F31.USD","BK4588","IE00B64PRP62.GBP","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","SG9999014005.SGD","LU0314104364.USD","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662206211","title":"Tempest Therapeutics - Justin Trojanowski to Resign as Principal Financial Officer and Principal Accounting Officer Effective Sept 1 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2662206211","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662206211?lang=en_us&edition=fundamental","pubTime":"2026-08-25 04:44","pubTimestamp":1787604263,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nFWN44L0AE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TPST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662062192","title":"Tempest Therapeutics - Appoints Nicholas Rossettos as CFO, Principal Financial and Accounting Officer Effective Sept 1, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2662062192","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662062192?lang=en_us&edition=fundamental","pubTime":"2026-08-25 04:44","pubTimestamp":1787604263,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nFWN44L0AE:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TPST","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662062462","title":"Tempest Therapeutics Names Nicholas Rossettos CFO, Replacing Justin Trojanowski","url":"https://stock-news.laohu8.com/highlight/detail?id=2662062462","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662062462?lang=en_us&edition=fundamental","pubTime":"2026-08-25 04:44","pubTimestamp":1787604242,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics names Nicholas Rossettos CFO, replacing Justin TrojanowskiTempest Therapeutics’ principal financial and accounting officer Justin Trojanowski will resign effective Sept. 1, 2026.N","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nNDL48bpV9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TPST","BK4139","RNAZ","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661290810","title":"Tempest Therapeutics - Files to Offer up to 8,910,579 Shares - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2661290810","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661290810?lang=en_us&edition=fundamental","pubTime":"2026-08-22 04:47","pubTimestamp":1787345251,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nFWN44I0Y1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TPST","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660338492","title":"Tempest Therapeutics Special Meeting Adjourned After Proposal Fell Short of Required Votes","url":"https://stock-news.laohu8.com/highlight/detail?id=2660338492","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660338492?lang=en_us&edition=fundamental","pubTime":"2026-08-19 04:28","pubTimestamp":1787084902,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics special meeting adjourned after proposal fell short of required votesTempest Therapeutics held a reconvened special shareholder meeting on Aug. 17, 2026.Shareholders did not adopt","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nNDLc8MKSH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TPST","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tempesttx.com","stockEarnings":[{"period":"1week","weight":-0.1436},{"period":"1month","weight":-0.2324},{"period":"3month","weight":-0.2324},{"period":"6month","weight":-0.5208},{"period":"1year","weight":-0.911},{"period":"ytd","weight":-0.7111}],"compareEarnings":[{"period":"1week","weight":0.0127},{"period":"1month","weight":0.0069},{"period":"3month","weight":0.0581},{"period":"6month","weight":0.2165},{"period":"1year","weight":0.1722},{"period":"ytd","weight":0.1311}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.461538,"avgChangeRate":0.012727},{"month":2,"riseRate":0.307692,"avgChangeRate":-0.032927},{"month":3,"riseRate":0.461538,"avgChangeRate":0.000618},{"month":4,"riseRate":0.307692,"avgChangeRate":-0.113004},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.011916},{"month":6,"riseRate":0.285714,"avgChangeRate":-0.124765},{"month":7,"riseRate":0.214286,"avgChangeRate":-0.03977},{"month":8,"riseRate":0.428571,"avgChangeRate":-0.030843},{"month":9,"riseRate":0.5,"avgChangeRate":-0.072102},{"month":10,"riseRate":0.461538,"avgChangeRate":0.94597},{"month":11,"riseRate":0.384615,"avgChangeRate":-0.081423},{"month":12,"riseRate":0.307692,"avgChangeRate":-0.062561}],"exchange":"NASDAQ","name":"Tempest Therapeutics Inc.","nameEN":"Tempest Therapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Tempest Therapeutics Inc.(TPST),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Tempest Therapeutics Inc.(TPST) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Tempest Therapeutics Inc.,TPST,Tempest Therapeutics Inc.股票,Tempest Therapeutics Inc.股票老虎,Tempest Therapeutics Inc.股票老虎国际,Tempest Therapeutics Inc.行情,Tempest Therapeutics Inc.股票行情,Tempest Therapeutics Inc.股价,Tempest Therapeutics Inc.股市,Tempest Therapeutics Inc.股票价格,Tempest Therapeutics Inc.股票交易,Tempest Therapeutics Inc.股票购买,Tempest Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Tempest Therapeutics Inc.(TPST),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Tempest Therapeutics Inc.(TPST) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}